Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of ODM-106 in Healthy Males
NCT02393950Phase 1Completed
- Sponsor
- Orion Corporation
- Start
- Mar 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in essential tremor (ET) comparing ODM-106 with Placebo (2 arms). Primary endpoint: Number of Participants With Adverse Events as a Measure of Safety and Tolerability up to 16 weeks. Started Mar 2015; status: completed.
02
Drugs
ODM-106
03
Conditions
essential tremor (ET)
Beyond the preview
Go deeper on NCT02393950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02393950.